Lonza Will Manufacture Asher Bio's Cis-targeted IL-2 Fusion Protein
Asher Biotherapeutics, which is developing targeted immunotherapies for cancer, autoimmune, and infectious diseases, and Lonza, a CDMO, signed a manufacturing agreement for AB359, a cis-targeted IL-2 fusion pr…
Read guide →